What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.”In the company’s words, NCT03943004 on ClinicalTrials.gov
- Tested for
- Solid Tumor, Cancer
- Main trialPhase 1
- “This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.”In the company’s words, NCT03943004 on ClinicalTrials.gov
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 1 Mar 2026 | Trial of DFP-14927 in Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026